Liver Diseases  >>  setrobuvir (AN598)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
setrobuvir (AN598) / Roche
NCT00782353: Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection

Completed
1
35
US
ANA598 200 mg bid or placebo, ANA598 400 mg bid or placebo, ANA598 800 mg bid or placebo
Hoffmann-La Roche
Chronic Hepatitis C
03/09
03/09

Download Options